Compare VIVS & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIVS | SBFM |
|---|---|---|
| Founded | 2007 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1M | 2.2M |
| IPO Year | 2010 | 2008 |
| Metric | VIVS | SBFM |
|---|---|---|
| Price | $0.28 | $2.33 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 898.1K | 292.1K |
| Earning Date | 11-12-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $4,603,000.00 | ★ $36,305,891.00 |
| Revenue This Year | $228,144.28 | $1.23 |
| Revenue Next Year | N/A | $22.44 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 8.82 | 4.11 |
| 52 Week Low | $0.12 | $0.13 |
| 52 Week High | $3.40 | $15.00 |
| Indicator | VIVS | SBFM |
|---|---|---|
| Relative Strength Index (RSI) | 75.73 | 54.36 |
| Support Level | $0.27 | $2.01 |
| Resistance Level | $0.30 | $3.05 |
| Average True Range (ATR) | 0.03 | 0.18 |
| MACD | 0.01 | -0.10 |
| Stochastic Oscillator | 88.82 | 0.02 |
VivoSim Labs Inc is a pharmaceutical and biotechnology services company focused on testing drugs and drug candidates in three-dimensional human tissue models of the liver and intestine. The Company provides liver and intestinal toxicology insights using its new approach methodologies and models and offers liver toxicology predictive screening and research services, as well as services to predict and study the intestinal side effect profiles of therapeutic candidates at all stages of drug development. Its 3D human tissue platform includes expertise in 3D organoids, such as spheroids, and proprietary cell culture techniques.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.